Redx Pharma plc Exercise of Options and Total Voting Rights (2212M)
11 October 2016 - 7:32PM
UK Regulatory
TIDMREDX
RNS Number : 2212M
Redx Pharma plc
11 October 2016
11 October 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Exercise of Options and Total Voting Rights
Redx, the drug development company, announces that it has
received notice from employees of the Company to exercise share
options over an aggregate of 145,319 ordinary shares of 1p each in
the Company ("Ordinary Shares"). The exercise price is 50p for
110,025 Ordinary Shares and 42.5p for the remaining 35,294 Ordinary
Shares.
Application has been made for the 145,319 new Ordinary Shares to
be admitted to trading on AIM ("Admission") and it is expected that
Admission will commence on 17 October 2016. The new Ordinary Shares
will rank pari passu with the Company's existing Ordinary
Shares.
The total number of Ordinary Shares in issue following Admission
will be 93,697,957. Accordingly, the figure of 93,697,957 may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure and Transparency Rules.
For further information, please contact:
Redx Pharma Plc
Neil Murray, Chief Executive T: +44 151
706 4747
Karl Hård, Head of Investor T: +44 7491
Relations & 651 406
Corporate Communications
Cantor Fitzgerald Europe (Nomad T: +44 20
& Broker) 7894 7000
Phil Davies/ Michael Reynolds
KTZ Communications T: +44 20
3178 6378
Katie Tzouliadis/ Viktoria Langley/
Emma Pearson
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a portfolio of 14 proprietary drug programs. Seven
proof of concepts have been achieved across five programs, with
relevance for respective therapies to treat MRSA, gonorrhea, bone
tumours, skin, brain, breast, pancreatic and blood cancers.
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEGGGGWUUPQURG
(END) Dow Jones Newswires
October 11, 2016 04:32 ET (08:32 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024